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The external subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env),
gp120, contains conserved regions that mediate sequential interactions with two cellular receptor molecules,
CD4 and a chemokine receptor, most commonly CCR5 or CXCR4. However, antibody accessibility to such
regions is hindered by diverse protective mechanisms, including shielding by variable loops, conformational
flexibility and extensive glycosylation. For the conserved neutralization epitopes hitherto described, antibody
accessibility is reportedly unrelated to the viral coreceptor usage phenotype. Here, we characterize a novel,
conserved gp120 neutralization epitope, recognized by a murine monoclonal antibody (MAb), D19, which is
differentially accessible in the native HIV-1 Env according to its coreceptor specificity. The D19 epitope is
contained within the third variable (V3) domain of gp120 and is distinct from those recognized by other
V3-specific MAbs. To study the reactivity of MAb D19 with the native oligomeric Env, we generated a panel of
PM1 cells persistently infected with diverse primary HIV-1 strains. The D19 epitope was conserved in the
majority (23/29; 79.3%) of the subtype-B strains tested, as well as in selected strains from other genetic
subtypes. Strikingly, in CCR5-restricted (R5) isolates, the D19 epitope was invariably cryptic, although it could
be exposed by addition of soluble CD4 (sCD4); epitope masking was dependent on the native oligomeric
structure of Env, since it was not observed with the corresponding monomeric gp120 molecules. By contrast,
in CXCR4-using strains (X4 and R5X4), the epitope was constitutively accessible. In accordance with these
results, R5 isolates were resistant to neutralization by MAb D19, becoming sensitive only upon addition of
sCD4, whereas CXCR4-using isolates were neutralized regardless of the presence of sCD4. Other V3 epitopes
examined did not display a similar divergence in accessibility based on coreceptor usage phenotype. These
results provide the first evidence of a correlation between HIV-1 biological phenotype and neutralization
sensitivity, raising the possibility that the in vivo evolution of HIV-1 coreceptor usage may be influenced by the
selective pressure of specific host antibodies.
The envelope glycoprotein (Env) of human immunodefi-
ciency virus (HIV), the etiologic agent of AIDS (16), consists
of two noncovalently bound subunits derived from the gp160
precursor: the external subunit, gp120, which mediates the
virion attachment to the target cell surface, and the transmem-
brane subunit, gp41, which initiates the process of fusion be-
tween the viral and cellular membranes (66). On the surface of
virions or infected cells, the native Env is present as an oli-
gomer of gp120/gp41 complexes. The mechanism whereby the
virus enters specific target cells involves sequential interactions
of gp120 with two highly conserved cell surface receptor mol-
ecules: the CD4 glycoprotein (32) and a chemokine receptor,
referred to as a coreceptor, most commonly CCR5 or CXCR4
(1). The chemokines that naturally bind such coreceptors act as
specific inhibitors of HIV infection (31). The differential usage
of coreceptors, which is critically dependent on the sequence,
charge, and/or structure of the third variable (V3) region of
gp120 (7, 8), dictates the viral phenotype, which shows a typical
pattern of evolution during the natural history of HIV-1 infec-
tion. CCR5-restricted (R5) strains are the most prevalent in
vivo, as they are almost invariably responsible for the initial
transmission, predominate during the long asymptomatic
phase of the infection, and often persist after the progression
to full-blown AIDS; by contrast, strains that utilize CXCR4,
either alone (X4) or in combination with CCR5 (R5X4),
emerge only in a subset of patients, typically in conjunction
with the onset of clinical signs of disease progression and
immune system deterioration (10, 49).
Like most RNA viruses, HIV is characterized by a marked
genetic and antigenic variability. Due to its critical role in the
early virus-cell interactions and its exposure on the virion sur-
face, the gp120 Env subunit is particularly subjected to the
selective pressure of the host humoral immune response. How-
ever, the need to specifically recognize highly conserved cellu-
* Corresponding author. Mailing address: Unit of Human Virology,
Department of Biological and Technological Research (DIBIT), San
Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
Phone: 39-02-26432821. Fax: 39-02-26434905. E-mail: paolo.lusso@hsr
.it.
6957
lar receptor structures restricts the degree of variation that the
virus can tolerate at selected gp120 sites. Such conserved re-
gions include the CD4-binding site, a discontinuous region at
the interface between the inner and outer domains of gp120
(27), and the so-called “bridging sheet,” which connects the
two gp120 domains and contributes the largest surface of the
coreceptor-binding site (27, 44). To compensate for the oblig-
atory antigenic conservation of such gp120 regions, the virus
has nevertheless evolved an extraordinary array of protective
mechanisms that provide an effective shield from neutralizing
antibodies (66). One of the most remarkable mechanisms is
the cryptic conformation of the coreceptor-binding site, which
is poorly accessible on the native virion surface but is either
unmasked, stabilized, or de novo formed after CD4 binding
(27, 44), a process that induces dramatic conformational
changes in gp120 (34, 46, 55, 56, 57, 63, 65); this complex
region encompasses most of the so-called CD4-induced
(CD4i) epitopes (56, 65, 67). Another major protection device
is the physical shield provided by the variable loops V1/V2 and
V3. In native virions, such structures are positioned to cover an
extended surface of gp120, which includes most of the core-
ceptor-binding site and part of the CD4-binding site, but they
are displaced away following CD4 binding (3, 27, 34, 55, 65).
The variable loops represent poor targets for broadly neutral-
izing antibodies, due to a high degree of tolerance to antigenic
variation. Additional mechanisms of gp120 evasion from anti-
body-mediated control include oligomerization, as illustrated
by the lack of correlation between antibody binding to mono-
meric gp120 and neutralization (15, 37, 47); conformational
flexibility (26), which reduces the immune system ability to
obtain a sharply focused image of the major neutralization
epitopes; and an extraordinary degree of surface glycosylation
(up to 50% of the entire gp120 molecular mass), which can
disguise epitopes to appear as “self” to the immune system (27,
64). All the above protective mechanisms are fully operational
in primary HIV-1 strains, which generally display a neutraliza-
tion-resistant phenotype, but their effectiveness is progressively
reduced after multiple in vitro passages, as is the case for X4
strains adapted to growth in continuous T-cell lines, which
exhibit the highest sensitivity to antibody-mediated neutraliza-
tion (2, 12, 17, 33, 37, 52, 62, 68).
Several studies with primary HIV-1 strains have suggested
that neutralization by defined monoclonal antibodies (MAbs),
as well as by sera from HIV-infected patients, is independent
of the viral coreceptor preference (6, 28, 36, 58), leading to the
conclusion that the selective pressure exerted by specific host
antibodies is not a major factor driving the phenotypic switch
from CCR5 to CXCR4 usage during the progression of the
disease. However, this conclusion was largely based on results
obtained by parallel testing of individual dualtropic (R5X4)
isolates on cells expressing different coreceptors (CXCR4 or
CCR5), rather than by direct comparison of different groups of
primary isolates to verify the inherent neutralization sensitivity
of each coreceptor usage phenotype (R5 versus R5X4 versus
X4). The latter approach was undertaken in one study (58), but
three of the four primary R5 viruses used (SF162, JR-FL, and
ADA) have been passaged in vitro multiple times; noticeably,
the only bona fide primary isolate was quite resistant to neu-
tralization by both the human MAb 2G12 and soluble CD4
(sCD4). In a few other reports, despite the limited number of
primary HIV-1 strains analyzed, R5 viruses exhibited an over-
all neutralization sensitivity lower than that of CXCR4-using
viruses (2, 4, 6, 53). Thus, the relationship between HIV-1
coreceptor phenotype and neutralization sensitivity has yet to
be definitively elucidated.
In this study, we characterized a novel conserved neutraliza-
tion epitope in the V3 domain of HIV-1 gp120. By analysis of
a large panel of primary and laboratory HIV-1 isolates, we
documented a consistent correlation between the exposure of
such epitopes in the native Env oligomer and viral coreceptor
usage phenotype: the epitope was constitutively exposed in
CXCR4-using strains, but it was invariably cryptic in R5
strains, although it became detectable upon CD4 binding, pro-
viding the first example of a CD4i epitope within the V3 loop.
These results may help to elucidate the mechanisms underlying
the coreceptor evolution of HIV-1 in vivo and may be relevant
to current efforts to develop a vaccine capable of eliciting
broadly neutralizing antibodies against HIV-1.
MATERIALS AND METHODS
Monoclonal and polyclonal antibodies. MAb D19 was obtained by standard
technology from a hybridoma derived by fusing mouse myeloma Sp2/0 with
splenocytes of mice immunized with recombinant oligomeric preparations of
uncleaved gp140 from a molecular clone (BH8) derived from the T-cell line-
adapted X4 HIV-1 isolate IIIB (16). The human anti-V3 loop MAb B4e8 (5) and
the anti-gp120MN goat antiserum (PB1MN), directed against a long V3-contain-
ing linear peptide (PB1; amino acids 295 to 474), were obtained from the
National Institutes of Health (NIH) AIDS Research and Reference Reagent
Program, National Institute of Allergy and Infectious Diseases (NIAID), Rock-
ville, MD. Human anti-V3 MAbs 268-D and 447-52D (9, 19) were a kind kift of
S. Zolla-Pazner, New York, N.Y. The hyperimmune serum against the V3BaL
loop (RV3) was obtained by immunization of a rabbit with a KLH-conjugated
cyclic peptide corresponding to the full-length V3 loop sequence of HIV-1 BaL
(V3BaL 1-36cyc).
Recombinant molecules and synthetic peptides. A recombinant, soluble, trun-
cated molecule encompassing the two outer domains (D1 and D2) of CD4
(sCD4); recombinant HIV-1 gp120 proteins from HIV-1 isolates BaL, IIIB,
SF162, MN and SF2, all produced in mammalian cells; and overlapping 15-mer
synthetic peptides derived from gp120 of HIV-1 MN were obtained from the
NIH AIDS Research and Reference Reagent Program. All the other synthetic
peptides were produced by standard solid-phase protocols using 9-fluorenylme-
thoxy carbonyl chemistry and purified by reversed-phase high-performance liquid
chromatography to 95% purity.
Viruses and persistently infected cell lines. HIV-1 isolates 91US714,
93BR020, 93US076, 92US077, 92UG024, 93US143, SF162, BaL, JR-FL, JR-
CSF, IIIB, SF2, and MN were obtained from the NIH AIDS Research and
Reference Reagent Program. Pediatric primary isolates from northern Italy
(IT224.1, IT224.18, IT306.9, IT380.6, IT145.4, IT204.1, IT136.34, and IT193.21)
were derived in the laboratory of one of us (G.S.) by cocultivation of patient
peripheral blood mononuclear cells (PBMC) with activated PBMC from healthy
blood donors, as previously described (49). All the remaining primary HIV-1
isolates, with the exception of B117, which was kindly provided by Eva M. Fenyo
(Lund University, Sweden), were obtained from the NIBSC-MRC AIDS Re-
agent Project (London, United Kingdom) within the framework of the World
Health Organization-Joint United Nations Programme on HIV/AIDS Network
for the Characterization of Globally Prevalent HIV-1 Strains in Relation to
Vaccine Development. All HIV-1 isolates were expanded and titrated in acti-
vated human PBMC, as previously reported (49). Primary isolates were mini-
mally passaged in vitro. For isolates CM235, CM243, 89.6, and BK132, the
cloned Env genes were expressed in HeLa cells using recombinant vaccinia virus
vectors.
The PM1 cell clone and its persistent infection with biologically diverse HIV-1
strains have previously been described (30). Chronically infected PM1 cell lines
were obtained for all the aforementioned HIV-1 isolates, with the exception of
isolate IIIB and its molecular clone, LW, for which chronically infected SupT1
cell lines were derived. To produce the chronically infected cell lines, the cells
were exposed to the viral stocks at an approximate multiplicity of infection of 0.1;
cultured in complete RPMI 1640 medium (Gibco) supplemented with 10%
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heat-inactivated fetal bovine serum (HyClone), 2 mM L-glutamine, and antibi-
otics (Gibco); and monitored daily for cytopathic effects and for extracellular p24
antigen release by enzyme-linked immunosorbent assay (ELISA) with commer-
cial antibodies (Aalto Bio Reagents, Dublin, Ireland). At the peak of the cyto-
pathic effects (typically, day 7 to 10 postinfection), the cells were pelleted, washed
once in prewarmed complete medium, and then cultured at low cellular density
(5  104 cells/ml) with daily replacement of half of the culture medium in the
presence of conditioned supernatants (20% [vol/vol]) from uninfected PM1 (or
SupT1). In most cases, this treatment resulted in the appearance within 10 to 14
days of small clusters of healthy-appearing cells that rapidly recolonized the
cultures. These outgrowing cell lines were shown to be chronically infected by
their stable cell surface expression of surface viral Env over time and by their
sustained release of extracellular p24 antigen.
Sequence analysis of the V3 loop. Sequence analysis of the V3 loop of isolates
for which no sequence was available in public databases was performed as
previously described (48). Briefly, DNA extracted from 2  106 PBMC infected
with each isolate was amplified by nested PCR (outer primers, JA9 and JA12;
nested primers, JA53 and JA10). The amplified products were directly se-
quenced using the Thermosequenase sequencing kit (Amersham Pharmacia)
according to the manufacturer’s indications, with both forward and reverse
fluorescein-labeled primers in an automated laser fluorescent sequencing appa-
ratus (ALF Red; Pharmacia LKB).
Fluorocytometry and MAb-binding competition assays. For fluorocytometric
analysis, 5 105 cells were incubated for 30 min at 4°C with 0.2 g of the relevant
MAb in 100 l of phosphate-buffered saline (PBS) (Gibco); in some experi-
ments, the cells were previously incubated with recombinant sCD4 (0.5 g/
sample). Cells treated with an irrelevant, isotype-matched MAb were used as
negative controls. Affinity-purified, phycoerythrin-conjugated polyclonal goat an-
ti-mouse or anti-human antibody (Sigma, St. Louis, MO) was used as a secondary
reagent. Samples were analyzed with a FACScan cytometer (Becton-Dickinson)
acquiring at least 10,000 events for each sample.
ELISA assays. Flat-bottom, 96-well ELISA plates (Immunol; PBI Interna-
tional, Milan, Italy) were coated with synthetic peptides (0.5 g/well) or with
recombinant HIV-1 gp120 (0.05 g/well) in PBS (50 l/well) for 18 h at 4°C.
Bovine serum albumin (1% in PBS) was used for blocking the plates. Antibodies
were added in 100 l PBS and incubated for 1 h at room temperature, after
which the plate was washed and incubated for an additional hour with the
secondary antibody. Peroxidase-conjugated, affinity-purified goat anti-mouse im-
munoglobulin G (IgG), goat anti-human IgG, goat anti-rabbit IgG, or swine
anti-goat IgG (all from Sigma) were used as secondary antibodies. After the
plates were washed, the reaction was revealed with an appropriate substrate.
Acute HIV-1 infection assay. PBMC were isolated by Ficoll-Hypaque (Phar-
macia) gradient centrifugation from concentrated leukocytes of healthy blood
donors and stimulated with 10 g/ml phytohemagglutinin (Sigma) in complete
RPMI medium. Infection was performed by exposing cells (105/well) to the viral
stocks (50 50% tissue culture infective doses/well) in duplicate 96-well round-
bottom microtiter plates in 200 l of complete RPMI medium supplemented
with 50 U/ml of recombinant interleukin-2 in the presence or absence of inhib-
itors. After incubation at 37°C for 16 h, the wells were washed twice and recul-
tured in complete medium with or without the inhibitors. After 48 h, 75% of the
culture supernatant was removed from each well for HIV-1 p24 antigen mea-
surement and replaced by an equal volume of fresh medium containing inter-
leukin-2 and the respective inhibitors. Virus replication was assayed by p24
antigen ELISA at days 3, 5, and 7 postinfection.
HIV-1 Env-mediated cell fusion assays. To assess HIV-1 Env-mediated fusion,
effector cells expressing HIV-1 Env (infected with vaccinia recombinant vT7
encoding bacteriophage T7 RNA polymerase) were mixed with target cells ex-
pressing the appropriate receptors (infected with vaccinia recombinant vCB21R
containing the Escherichia coli lacZ reporter gene linked to the T7 promoter) in
96-well plates (105 each cell type per well) and incubated at 37°C; after 2 h, the
cells were lysed with a nonionic detergent, and -galactosidase activity was
quantitated by spectrophotometry. The effector cells were either chronically
infected T-cell lines (PM1 or SupT1) or HeLa cells expressing recombinant Env
by a vaccinia virus vector, whereas the target cells were NIH 3T3 mouse fibro-
blast cells stably expressing human CCR5 or CXCR4 with or without human
CD4. The assay was performed using either the standard format with target cells
expressing both CD4 and the appropriate coreceptor (41) or the sCD4-activated
format with target cells expressing the coreceptor only (45).
RESULTS
Characterization of the D19 epitope. MAb D19 was ob-
tained by immunizing mice with a recombinant oligomeric
purified preparation of HIV-1 gp140, derived from the BH8
molecular clone of IIIB, a T-cell line-adapted X4 isolate.
Gp140 is an uncleaved, truncated, soluble glycoprotein con-
taining the entire extracellular region of HIV-1 Env, i.e., gp120
and the extracellular portion of gp41 (14). Hybridomas were
screened by immunoprecipitation of the gp140 protein, thus
allowing for the identification of MAbs recognizing conforma-
tional as well as linear epitopes. Preliminary epitope charac-
terization indicated that MAb D19 reacts with the V3 loop
region of gp120 (14). For a more detailed epitope mapping, we
tested MAb D19 reactivity with a series of V3-derived synthetic
peptides by ELISA; for comparison, three previously described
V3-specific, isolate-unrestricted human MAbs, B4e8, 268-D,
and 447-52D, were tested in parallel. As shown in Table 1, two
anti-V3 hyperimmune rabbit sera used as positive controls
(PB1MN and RV3BaL) recognized all the V3-derived peptides
tested. MAb D19 reacted strongly with a IIIB-derived 23-mer
linear peptide (IIIB 7-29), centered around the GPGR motif at
the tip of the V3 loop, as well as with peptides derived from
two distinct HIV-1 isolates, a colinear peptide from HIV-1 MN
(MN 6-28) and a cyclic, disulfide-bonded peptide encompass-
ing the entire V3 loop sequence of HIV-1 BaL (BaL 1-36cyc),
thus demonstrating that MAb D19 reactivity is not isolate
specific.
TABLE 1. Peptide mapping analysis of V3-specific monoclonal and polyclonal antibodies
V3 peptide Amino acid sequence
Reactivitya
D19 B4e8 268-D 447-52 PB1MN RV3
IIIB 7–29 NTRKSIRIQRGPGRAFVTIGK–IG     NT 
BaL 1–36cyc CTRPNNNTRKSIHI––GPGRAFYTTGEEIIGDIRQAHC      
MN 6–28 YNKRKRIHI––GPGRAFYTTKN–IIG      
MN 1–15 CTRPNYNKRKRIHI––G      
MN 5–19 NYNKRKRIHI––GPGRA      
MN 9–23 RKRIHI––GPGRAFYTT      
MN 13–27 HI––GPGRAFYTTKN–II      
MN 17–31 GRAFYTTKN–IIGTIR      
MN 21–35 YTTKN–IIGTIRQAHC      
MN 9–18 RKRIHI––GPGR      
a Reactivity was scored as follows:, below the threshold of background signal, calculated as the mean ELISA OD values from replicate negative controls (no peptide
bound) plus 3 times the standard deviation of the negative controls; , OD of 	 0.5; , OD of 0.5 to 1.0; , OD of 1.0 to 1.5; , OD of 1.5; NT, not tested.
All the MAbs were used at a concentration of 2.5 g/ml; the hyperimmune antisera were used at a final dilution of 1:40.
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Next, we tested a series of overlapping 15-mer peptides
spanning the entire V3 loop sequence of isolate HIV-1 MN.
Strikingly, MAb D19 was reactive with only one such peptide
(MN 9-23), which encompasses the conserved V3 loop tip
motif (GPG), as well as flanking sequences on both sides, while
no reactivity was observed with the two contiguous peptides,
MN 5-19 and MN 13-27, containing only two amino acids on
the C- and N-terminal sides, respectively, of the tip; likewise,
no signal was detected against a 10-mer peptide (MN 9-18)
nested within peptide MN 5-19. Thus, the integrity of the D19
epitope requires the presence of flanking sequences on both
sides of the V3 loop tip.
A reactivity pattern similar to that of MAb D19 was seen
with the human MAb B4e8 (5) even though, in accordance
with previous data using IIIB-derived recombinant gp120,
MAb B4e8 failed to recognize the IIIB-derived peptide MN
7-29. A distinct peptide recognition pattern was observed with
MAb 447-52D, which recognizes a wide range of HIV-1 strains
of different genetic subtypes (9, 18, 19), and with 268-D, which
is more restricted in its reactivity (19). Both MAbs reacted not
only with the tip-centered peptide (MN 9-23), but also with the
contiguous peptide on the N-terminal side (MN 5-19), as well
as with the 10-mer peptide V3MN 9-18, suggesting that the
presence of sequences on the C-terminal side of the loop is not
essential for their epitope configuration. These data are con-
sistent with the previously suggested minimal core epitope
requirements for the two MAbs (GPxR for 447-52D; HIGPGR
for 268-D) (19), as recently confirmed for 447-52D by both
nuclear magnetic resonance (51) and crystal structural studies
(54). Altogether, these observations suggest that the D19
epitope is distinct from those recognized by B4e8, 268-D, or
447-52D.
Monomeric HIV-1 gp120: D19-epitope accessibility is unre-
lated to coreceptor usage phenotype. To evaluate whether the
D19 epitope is accessible on the correctly folded gp120 glyco-
protein, we tested the ELISA reactivity of MAb D19 with
recombinant gp120 (predominantly monomeric) obtained
from three distinct HIV-1 isolates, two R5 (BaL and SF162)
and one X4 (IIIB). As illustrated in Fig. 1, MAb D19 was able
to bind monomeric gp120 from all three isolates in a dose-
dependent fashion. As a proof of specificity, preadsorption
with peptide BaL 1-36cyc at 100 g/ml virtually abrogated the
reactivity. With all the gp120 preparations tested, pretreatment
with sCD4 induced a very limited increase in MAb D19-bind-
ing activity. Similar results, i.e., binding to recombinant gp120
with limited increase upon sCD4 treatment, were obtained
using other MAbs directed against the V3 loop (447-52D and
268-D) or against well-characterized CD4i epitopes (17b and
48d) (data not shown). These results indicate that the D19
epitope is readily accessible on monomeric gp120 molecules
derived from different HIV-1 strains, regardless of their core-
ceptor specificities.
Native oligomeric HIV-1 Env: D19-epitope accessibility cor-
relates with coreceptor usage phenotype. To evaluate the re-
activity of MAb D19 within the context of the native, oligo-
meric Env, we derived T-cell lines persistently infected with
different HIV-1 isolates; the parental cell was a unique CD4
T-cell clone, PM1, which expresses both CXCR4 and CCR5
and shows a broad sensitivity to infection by, as well as primary,
laboratory-adapted HIV-1 isolates, irrespective of their core-
ceptor usage phenotype and genetic subtype (30). PM1 cells
were infected with four viral isolates displaying different core-
ceptor usage phenotypes, i.e., IIIB (X4), 92US077 (R5X4),
BaL (R5), and 91US714 (R5); since efforts to obtain PM1 cells
stably infected with isolate IIIB were unsuccessful, the CD4
T-cell line SupT1 was utilized for this strain. Stable popula-
tions of chronically infected cells were obtained after several in
vitro passages. All the cell lines continued to release extracel-
lular p24 antigen for prolonged periods (3 months) in the
absence of syncytium formation or other evident cytopathic
effects; moreover, they stably expressed the native Envs on the
cell surface, as shown by immunostaining using a panel of
specific MAbs and by testing their fusogenic activities in a
vaccinia-based assay (data not shown). Of note, all persistently
infected cell lines exhibited no detectable surface CD4 expres-
sion, thus ruling out the possible formation of cell surface-
bound complexes between residual CD4 and released virions
or shed soluble gp120, which is a potential confounding factor
in the analysis of the native Env on infected cells (38). Absence
FIG. 1. Reactivity of MAb D19 with monomeric gp120. ELISAs
were performed by using recombinant gp120 in the solid phase in the
presence or absence of sCD4. Recombinant gp120 glycoproteins from
one X4 isolate (IIIB) and two R5 HIV-1 isolates (BaL and SF162)
were produced in mammalian cells. The specificity of the reactions was
verified by preadsorption of MAb D19 with a full-length V3-derived
peptide (BaL 1-36cyc). The data shown are from a representative ex-
periment of two performed with similar results.
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of CD4 was documented by the lack of reactivity with MAbs
directed against different extracellular domains of CD4, as well
as with the CD4i MAbs 17b and 48d in the absence of exog-
enously added sCD4 (not shown).
As illustrated in Fig. 2, top two panels, MAb D19 was reac-
tive with cells infected with the two CXCR4-using HIV-1 iso-
lates (IIIB and 92US077), while no reactivity was seen in con-
trol experiments with the corresponding uninfected cells (not
shown). As a specificity validation, preadsorption of MAb D19
with a linear V3 loop peptide (MN 9-23) induced a marked
dose-dependent reduction of the fluorescent signal (not
shown). These results demonstrated that MAb D19 can effec-
tively recognize the native, oligomeric Env conformations of
these two CXCR4-using strains. By contrast, MAb D19 was
not reactive with cells infected with the R5 isolate BaL (Fig. 2,
third panel from top), in spite of the strong ELISA reactivity
previously observed with the BaL-derived cyclic peptide (BaL
1-36cyc) (Table 1), as well as with the recombinant homologous
gp120 (Fig. 1). Similarly, no reactivity was seen with the other
R5 isolate, 91US714. These data demonstrate that in the na-
tive, oligomeric Env conformation of these R5 isolates the D19
epitope is inaccessible to antibody binding. The contrasting
results obtained with monomeric versus oligomeric gp120 de-
rived from the same isolate (BaL) suggest that the cryptic
nature of the D19 epitope in the native, cell surface-expressed
Env conformation is due to oligomerization-dependent mask-
ing.
Induction of D19-epitope accessibility in native R5 Envs by
CD4 binding. To evaluate whether the antibody accessibility of
the D19 epitope was affected by the gp120 conformational
changes associated with CD4 binding, fluorocytometric analy-
sis was performed after treatment of Env-expressing cells with
sCD4. Strikingly, in cells infected with the R5 isolates BaL or
91US714, the D19 epitope became accessible to antibody bind-
ing upon treatment with sCD4 (Fig. 2, bottom two panels),
while its accessibility was only modestly enhanced in cells in-
fected with CXCR4-using isolates (Fig. 2, top two panels).
These findings suggest that in the native Env oligomer of R5
isolates, the D19 epitope is present in a cryptic conformation
but is either unmasked, stabilized, or de novo formed upon
CD4 binding, thereby fulfilling the definition of CD4i epitope.
Indeed, a similar pattern of sCD4-mediated epitope inducibil-
ity in PM1 cells persistently infected with BaL or 91US714 was
observed with two reference anti-CD4i human MAbs, 17b and
48d, directed against the “bridging-sheet” surface (not shown).
By contrast, other V3-specific reagents (human MAbs 447-
52D, 268D, and B4e8 and hyperimmune serum RV3) were
able to bind to PM1 cells infected with HIV-1 BaL or HIV-1
91US714 regardless of sCD4 treatment (not shown), indicating
that the lack of basal recognition by MAb D19 does not reflect
a cryptic conformation of the entire V3 domain. In accordance
with previous results (34, 53), however, all these antibodies
showed increased binding after treatment with sCD4.
Reactivity of MAb D19 with a panel of native HIV-1 Envs:
consistent correlation between epitope accessibility and core-
ceptor usage phenotype. To assess the breadth of reactivity of
MAb D19 and the consistency of the correlation between D19
epitope accessibility in native oligomeric Env and coreceptor
usage phenotype, we studied a large panel (n 
 43) of cell
surface-expressed Envs from both primary and laboratory-pas-
saged HIV-1 isolates (Table 2): 22 CCR5 specific (R5), 12
CXCR4 specific (X4), and 9 capable of using both coreceptors
(R5X4). Twenty-nine of the Envs tested belonged to genetic
subtype B (13 R5, 9 X4, and 7 R5X4), 2 to A (both R5), 5 to
C (all R5), 4 to D (3 X4 and 1 R5X4), 2 to E (both R5), and
1 to F (R5X4). Most of the Envs were analyzed using chron-
ically infected PM1 cell lines; the only exceptions were Envs
IIIB and LW, for which chronically infected SupT1 cells were
used, and Envs 89.6, BK132, CM235, and CM243, which were
analyzed using recombinant vaccinia vectors. Cell fusion assays
indicated that the Envs of isolates grown in chronically infected
PM1 or SupT1 cells retained the same coreceptor usage phe-
notype as the original isolate from which they were derived;
moreover, their reactivity with a panel of well-characterized
human MAbs (e.g., 2G12, IgG1b12, 2F5, 17b, 48d, 447-52D,
and 268-D) was unmodified (data not shown).
Analysis by fluorocytometry demonstrated the presence of
the D19 epitope in 25 (58.1%) of the 43 Envs tested, with a
similar prevalence among CCR5-specific (12/22; 54.5%) and
CXCR4-using (13/21; 61.9%) strains (Table 2). The most strik-
ing observation emerging from the analysis of the D19-reactive
FIG. 2. Fluorocytometric analysis of MAb D19 binding to the na-
tive Env expressed on the surface of cells persistently infected with
different HIV-1 strains. The cells, PM1 or SupT1, were persistently
infected with HIV-1 isolates of different coreceptor preference: IIIB
(X4), 92US077 (R5X4), BaL, and JR-FL (R5). The cells shown on the
right-hand panels were tested after treatment with sCD4. The data
shown for each viral strain are from a representative experiment of five
or more performed with similar results.
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Envs was the strict correlation between epitope accessibility in
the native, cell surface-expressed Env and coreceptor usage
phenotype. Thus, for all 12 R5 Envs, the D19 epitope was
invariably cryptic, although inducible upon CD4 binding; by
contrast, for all 13 CXCR4-using Envs (7 X4 and 6 R5X4), the
epitope was constitutively exposed independent of CD4 bind-
ing (Table 2).
The D19 epitope was highly conserved within genetic sub-
type B (23/29; 79%), which was the most represented sub-
type in our panel. Among the non-B strains tested, the
overall frequency of MAb D19 reactivity was significantly
lower (2/14; 14%), and variable between different subtypes:
the two reactive Envs belonged to subtypes A and F, while
no reactive Envs were found within subtypes C, D, and E
(Table 2). Although the number on non-B strains analyzed
was small, these data nevertheless indicate that MAb D19
reactivity is not restricted to genetic subtype B. Assessment
of the relationship between conservation of the D19 epitope
TABLE 2. MAb D19 reactivity with a panel of primary and in vitro-passaged HIV-1 Envsa
Isolate Envs subtype/coreceptor usage
MAb D19 reactivity
V3 loop aa sequence
sCD4 sCD4
D19-reactive
97TZ001 A/R5   CTRPNNNTRRGINI––GPGRAFYTTSD-IIGDIRQAHC
BaL B/R5   CTRPNNNTRKSIHI––GPGRAFYTTGEEIIGDIRQAHC
JRFL B/R5   CTRPNNNTRKSIHI––GPGRAFYTTGE–IIGDIRQAHC
JRCSF B/R5   CTRPNNNTRKSIHI––GPGRAFYTTGE–IIGDIRQAHC
SF162 B/R5   CTRPNNNTRKSITI––GPGRAFYATGD–IIGDIRQAHC
91US714 B/R5   CIRPNNNTRRSIHM––GPGRAFYATGD–IIGDIRQAHC
93US573 B/R5   CSRPNNNTRKSIHI––GPGGAIYKTGA–IIGDIRQAHC
IT224.1 B/R5   CTRPNNNTRKSINM––GPGRAFYTTGE–IIGDIRQAHC
IT224.18 B/R5   CTRPNNNTRKSINM––GPGRAFYITGQ–IIGNIRQAHC
IT306.9 B/R5   CIRPNNNTRKSIPM––GPGKAFYATGG–IIGNIRQAHC
IT380.6 B/R5   CTRPNNNTRKSIHM––GPGGAFYATGG–IIGDIRQAHC
IT145.4 B/R5   CTRPNNNTRKSIPI––GPGKAFYTTGD–IIGDIRQAHC
IIIB B/X4   CTRPNNNTRKRIRIQRGPGRAFVTIGK––IGNMRQAHC
LW B/X4   CTKPNNNTGKRIRIQRGPGRTFVTIGK––IGNMRQAHC
MN B/X4   CTRPNYNKRKRIHI––GPGRAFYTTKN–IIGTIRQAHC
SF2 B/X4   CTRPNNNTRKSIYI––GPGRAFHTTGR––IGDIRQAHC
IT204.1 B/X4   CTRPNNNTRKRITM––GPGRVYYTTGE–IIGNIRQAHC
BK132 B/X4   CTRPNNYTRKRITM––GPGRVYYTTGE–IIGNIRRAHC
451 B/X4   CTRPNNHTRKRVTL––GPGRVWYTTGE–ILGNIRQAHC
89.6 B/R5X4   CTRPNNNTRRRLSI––GPGRAFYARRN–IIGDIRQAHC
93USCW B/R5X4   CTRPNNNTRKRVTL––GPGRVWYTTGQ–IIGDINKAYC
98IN018 B/R5X4   CTRPNNNTSKRISL––GPGRVWYTTGO–IVGNIRQAHC
92US077 B/R5X4   CTRPNNNTRRRITM––GPGRVYYTTGD–IVGDIRRAHC
B117 B/R5X4   CTRPNNNTRKGIYI––CPGRAVYATRK–IIGDIRQAHC
93BR020 F/R5X4   CTRPNNNTRKYISL––GPGRVFYTTGE–IIGDIRKAHC
Consensus CTRPNNNTRKSIHI––GPGRAFYTTGE–IIGDIRQAHC
D19-nonreactive
97TZ002 A/R5   CIRPNNNT–RKSIRI–––GPGQTFYATGDIIGDIRQAYC
IT136.34 B/R5   CTRPNNNT–RRSIHI–––GPGKAFY–TGEIIGNIRKAHC
91US054 B/R5   CIRPNNYT–RKYIHI–––GPGRALYAHGDIIGDIRQAHC
93US076 B/X4   CSRPHTSK–RRGIRV–––GPGGAWFKTGDITGNIKQAHC
93US143 B/X4   CTRPNRNA–WKGIPIG––VPGRKFYARRNITGDIRQAYC
96USNG17 B/R5X4   CTRPNNNT–RKGIRI–––GPGRKVYATSAIIGDIRKAHC
IT193.21 B/R5X4   CTRPNNNT–RKSIRIGHIGPGRPIYATGGIIGDIRQAHC
98CN005 C/R5   CTRPNNNT–RKSIRI–––GPGQTFYATGEIIGDIRQAHC
98IN015 C/R5   CIRPNNNT–RKSIRI–––GPGQTFYATGDIIGDIRQAHC
98IN007 C/R5   CTRPNNNT–RKSIRI–––GPGQAFYARGDIIGNIRQAHC
97ZA001 C/R5   CTRPNNNT–RKSVRI–––GPGQAFFATGDIIGDIRQAHC
7TZ004 C/R5   CIRPNNNT–RKSIYI–––GPGQTFYATGDIIGDIRQAHC
7TZ007 D/X4   CTRPYKSV–RQRTSI–––GQGQALYTTRPTISIIGQAHC
98TZ011 D/X4   CTRPYYTI–RRSTHIG––GPGRAFY–TKNIIGNTRQAYC
92UG038 D/X4   CARPFYAIERQRTPI–––GQGQVLYTTKK–IGRIGQAHC
92UG024 D/R5X4   CTRPYNNI–RQRTPI–––GLGQALYTTRR–IEDIRRAHC
CM235 E/R5   CTRPSNNT–RTSIPI–––GPGYAFYYTGDIIGDIRKAYC
CM243 E/R5   CTRPSNNT–RPSITV–––GPGQVFYRTGDIIGDIRRAYC
Consensus CTRPNNNT–RKSIRI–––GPGQAFYATGDIIGDIRQAHCb
a The amino-acid (aa) sequences of the V3 loop of all the isolates studied have been aligned; amino acid differences from the consensus sequences are in boldface
type.
b Amino acid differences from the consensus sequence of D19-reactive isolates are in boldface and underlined.
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and genetic subtype awaits the analysis of a larger panel of
primary isolates.
Further definition of the D19 epitope by comparative anal-
ysis of V3 loop sequences from reactive and nonreactive HIV-1
isolates. In an attempt to refine our definition of the antigenic
boundaries of the D19 epitope, we compared the V3 loop
amino acid sequences from all the D19-reactive and -nonreac-
tive HIV-1 isolates included in this study (Table 2). The V3
consensus sequences of D19-reactive (n 
 25) and -nonreac-
tive (n 
 18) isolates differed at four positions (H133R,
R183Q, T223A, and E253D); among such differences, how-
ever, only R183Q clearly distinguished the two groups, being
specifically associated with the lack of MAb D19 reactivity,
whereas H133R discriminated the two groups only within the
R5 subset. Overall, we were unable to identify any other spe-
cific pattern that permitted the unambiguous identification of
either group; nonetheless, some distinctive features were more
commonly associated with the absence of the D19 epitope,
irrespective of the viral coreceptor usage phenotype. Besides
the Envs (n 
 9) displaying a Q at position 18 (GPGQ or
GQGQ motifs), several D19-nonreactive Envs showed non-
conservative amino acid changes on the C-terminal side of the
tip of the loop, including replacement of R18 by Y, replace-
ment of A19 or T22 by positively charged residues, replacement
of Y21 by F, or deletion of T22; also, in some D19-unreactive
isolates, there were 1- or 3-aa insertions N-terminal to the
GPG motif or amino acid changes in the GPG tip motif itself
(G153V, P163Q, and P163L). The tip motif was instead
100% conserved among D19-reactive isolates. Other residues
that were remarkably conserved among D19-reactive strains
included the positively charged residues at positions 10 and 18
and the isoleucine at position 12. In conclusion, despite the
lack of specific “signature” motifs consistently associated with
the presence or absence of the D19 epitope, this analysis re-
inforced the concept that the lack of recognition of certain
HIV-1 isolates by MAb D19 can be ascribed to genetic heter-
ogeneity within the V3 domain, which is subjected to a strong
selective pressure by the host humoral immune system.
Neutralization of primary HIV-1 strains by MAb D19: de-
pendence on sCD4 for neutralization of CCR5-dependent but
not CXCR4-using isolates. To evaluate the biological rele-
vance of the reactivity pattern of MAb D19 in relation to the
HIV-1 coreceptor usage phenotype, we investigated the ability
of this MAb to neutralize HIV-1 infection and Env-mediated
cell fusion. First, we tested neutralization of acute HIV-1 in-
fection in primary human PBMC using four viral strains of
different coreceptor usage phenotype: two extensively in vitro-
passaged isolates, IIIB (X4) and BaL (R5), and two primary
isolates, 92US077 (R5X4) and 91US714 (R5). The latter were
grown exclusively in primary PBMC for a limited number of in
vitro passages. As shown in Fig. 3, left, MAb D19 effectively
neutralized both of the CXCR4-using isolates, with mean 50%
inhibitory doses (ID50) of 0.16 and 0.38 g/ml, respectively; by
contrast, it had no effect against the two R5 isolates up to a
concentration of 100 g/ml. The neutralization tests were also
performed in the presence of subinhibitory concentrations of
sCD4 (10% inhibitory dose [ID10]), which were predetermined
for each isolate by PBMC infection assays. For the two R5
isolates, such doses were nonetheless sufficient to induce D19
epitope exposure in persistently infected PM1 cells (not
shown). The efficacy of MAb D19 against IIIB and 92US077
was virtually unaffected by sCD4 at ID10 concentrations. Strik-
ingly, however, the concomitant presence of sCD4 enabled
MAb D19 to neutralize both BaL and 91US714, with ID50
values of 0.65 and 15.4 g/ml, respectively. Thus, in agreement
with its binding pattern against the corresponding Env oli-
gomers expressed in chronically infected PM1 or SupT1 cells,
MAb D19 was able to constitutively neutralize the CXCR4-
using isolates, while neutralization of R5 isolates could only be
achieved in the presence of sCD4.
To extend the analysis of MAb D19 neutralization of pri-
mary and laboratory-adapted HIV-1 isolates, we performed
cell fusion assays, employing as effectors chronically infected
PM1 or SupT1 cells expressing physiological levels of surface
Env and cells expressing recombinant receptors as targets.
Passage in PM1 had no evident effects on several primary
HIV-1 strains with respect to their profiles of neutralization by
a panel of well-characterized human MAbs (2G12, IgG1b12,
2F5, 17b, 48d, 1570, 447-52D, and 268D) or by a reference pool
of human immune sera obtained from infected individuals (HIV-
Ig) (data not shown). Table 3 shows the neutralization sensitivities
of different HIV-1 isolates in two types of cell fusion assay. In
accordance with its binding pattern to the respective Env oli-
gomers, MAb D19 was able to block all the CXCR4-using strains
tested (one X4 and three R5X4) in the standard fusion assay
(target cells expressing CD4 and coreceptor), albeit with different
efficiencies; by contrast, it had no measurable effects on any of the
R5 strains tested, at doses up to 100 g/ml. In agreement with
previous observations (6, 28, 36, 58), individual R5X4 viruses
showed similar neutralization profiles irrespective of the corecep-
FIG. 3. Neutralization of different HIV-1 isolates by MAb D19 in the
presence or absence of sCD4. Phytohemagglutinin-activated human
PBMC, previously treated or not with MAb D19 at the indicated concen-
trations, were acutely infected with isolates IIIB (X4), 92US077 (R5X4),
BaL (R5), or 91US714 (R5). The MAb was maintained at the same
concentrations throughout the entire experiment; sCD4 was used at sub-
inhibitory concentrations (ID10) as predetermined for each virus strain by
PBMC infection assays: 0.25 g/ml for IIIB, 0.75 g/ml for 92US077, 0.5
g/ml for BaL, and 1.5 g/ml for 91US714. The levels of p24 antigen in
the culture supernatants were determined by ELISA at day 5 postinfec-
tion. The data indicate the means ( standard deviation) of triplicate
wells from one of two or three experiments performed with similar results.
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tor expressed on the target cells (CCR5 or CXCR4), supporting
the concept that the sensitivity to virus-neutralizing antibodies is
an inherent property of the viral Env and not of the composition
of the cellular receptor complex.
To ascertain whether CD4 binding-induced exposure of the
D19 epitope could render R5 isolates sensitive to neutralization
by MAb D19, we also used a sCD4-activated assay in which target
cells express the relevant coreceptor but not CD4; fusion is then
induced by addition of sCD4, which binds to Env, triggering the
gp120 conformational changes required for coreceptor binding.
In this assay (Table 3), all the CXCR4-using Envs displayed
sensitivity to MAb D19, generally at slightly lower doses than in
the standard test. Most dramatically, in contrast with the results
obtained in the standard assay, all the R5 Envs were highly sen-
sitive to neutralization by MAb D19 in the sCD4-activated assay.
Taken together, these data demonstrate a clear correlation be-
tween MAb D19 neutralization and binding to native Env: CCR5-
restricted Envs consistently display a cryptic D19 epitope that
becomes accessible only upon binding to CD4, while CXCR4-
using Envs constitutively expose the epitope both in the absence
and in the presence of sCD4.
Neutralization of R5 HIV-1 infection by other V3-specific
antibodies. To directly compare the neutralization pattern of
MAb D19 with that of other well-characterized antibodies to
the V3 loop, we evaluated the neutralizing activity of MAbs
B4e8 and 447-52D in the acute HIV-1 BaL infection assay in
primary human PBMC. The prototype CD4i MAb 17b, which
recognizes a complex “bridging-sheet” epitope, was used as a
control. Of note, MAbs B4e8 and 447-52D were able to bind to
the native cell surface-expressed HIV-1 BaL Env oligomer in the
absence of sCD4, whereas MAb 17b was not; however, treatment
with sCD4 induced de novo epitope accessibility for MAb 17b and
increased the binding of MAbs B4e8 and 447-52D (data not
shown). Figure 4 shows that the two anti-V3 MAbs were capable
of neutralizing HIV-1 BaL in the absence of sCD4, with mean
ID50 values of 0.75 and 0.22 g/ml, respectively; addition of sCD4
at subneutralizing concentration (ID10) did not significantly en-
hance their inhibitory activity, suggesting that even a limited
epitope accessibility is sufficient for effective neutralization by
such MAbs. By contrast, as documented with MAb D19, the
CD4i MAb 17b was per se ineffective against HIV-1 BaL, but it
was able to effectively neutralize viral replication when used in
combination with sCD4. Altogether, these results further distin-
guish MAb D19 from the other V3-specific MAbs tested, whereas
the biological similarity to MAb 17b reinforces the concept that
the D19 epitope behaves as a bona fide CD4i epitope, albeit in an
R5-restricted fashion.
DISCUSSION
The antigenic evolution of the HIV-1 Env in vivo is primarily
driven by the selective pressure of the host adaptive immune
responses, particularly neutralizing antibodies. Based on in
vitro neutralization studies, however, several authors have con-
cluded that neutralizing antibodies do not influence the evo-
FIG. 4. Neutralization of the RF5 HIV-1 isolate BaL by anti-V3
and anti-CD4i human MAbs. The assay used was the same as de-
scribed in the legend to Fig. 3. Two MAbs against the V3 loop (B4e8
and 447-52D) and one against the reference CD4i epitope 17b (rec-
ognizing the “bridging-sheet” surface) were tested. The data indicate
the means ( standard deviation) of triplicate wells from one of three
experiments performed with similar results.
TABLE 3. Ability of MAb D19 to neutralize cell fusion mediated by different HIV-1 Envs with cells expressing different coreceptors
Assay Coreceptor expressedon target cells
HIV-1 Envs expressed on isolate effector cells:a
X4 R5X4 R5
IIIB CW 077 89.6 JR-FL BaL 714
Standard CCR5 — 55.8 4.8 0.8 100 100 100
CXCR4 0.8 60.5 3.9 0.8 — — —
sCD4 activated CCR5 — NT 1.2 0.2 0.15 0.5 6.9
CXCR4 0.7 NT 1.6 0.15 — — —
a Complete designations of primary isolates: CW, 93USCW; 077, 92US077; 714, 91US714. All the Envs were expressed on the surface of chronically infected T-cell
lines with the exception of 89.6, which was expressed in HeLa cells using a recombinant vaccinia virus vector. Values are ID50 values (g/ml) with respect to
antibody-untreated cells used as a control. —, not applicable (no cell fusion with the indicated coreceptor); NT, not tested.
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lution of the HIV-1 coreceptor usage phenotype (28, 36, 58),
even though the two major gp120 structures that dictate the
use of different coreceptors, i.e., the V3 and V1/V2 loops, are
highly variable, as is characteristic of epitopes that are sub-
jected to selective immune pressure. In addition, several clin-
ical observations suggest the existence of an as-yet-undefined
negative pressure that hinders selectively the emergence of
CXCR4-using (i.e., X4 and R5X4) HIV-1 in individuals who
are still immunocompetent: (i) the exceptionally low rate of
established HIV-1 infection (de rigueur with CXCR4-using
strains) in people homozygous for the CCR5-32 allele (1), (ii)
the very infrequent expansion of CXCR4-using strains during
the asymptomatic phase of HIV-1 infection (10, 23, 25, 48, 49,
60), (iii) the often-transient replication of such strains even in
patients with progressive disease (21-23, 50), (iv) the prefer-
ential suppression of CXCR4-specific strains after initiation of
antiviral therapy (23, 43), (v) the lack of sustained increase of
CXCR4-tropic SHIV replication after treatment with a CCR5-
specific inhibitor in macaques dually infected with R5 and X4
viruses (61), and (vi) the selective clearance of CXCR4-using
strains from an initially mixed viral population (R5 plus X4)
documented in a few cases of acute primary infection (11, 29).
In the latter cases, the purging of CXCR4-using variants was
temporally associated with antibody seroconversion and in one
case specifically with the appearance of neutralizing antibodies
against the autologous virus (11, 29).
Altogether, the above considerations provide a rationale for
reevaluating the role played by neutralizing antibodies in the
evolution of coreceptor usage phenotype in HIV-infected peo-
ple. In this report, we provide the first conclusive evidence, to
our knowledge, of a correlation between antibody-mediated
HIV-1 neutralization and coreceptor usage phenotype, thus
establishing a proof of principle that antibodies may indeed
exert an influence on the coreceptor specificity of HIV-1. In
fact, we identified a unique V3 loop epitope (D19) that is
constitutively exposed by HIV-1 isolates that can use CXCR4
but is maintained in a cryptic conformation by CCR5-specific
strains, becoming accessible only after CD4 binding. It is con-
ceivable that the adoption of a more protected V3 loop con-
formation confers a selective advantage to R5 strains in an
immunocompetent host environment, as occurs during the
asymptomatic phase of the infection; given the crucial role of
the V3 loop in the HIV-1 infectivity process, however, a par-
tially cryptic conformation may be less favorable in terms of
viral fitness. By contrast, a better exposed V3 loop on the one
hand implies a reduced protection from antibody-mediated
neutralization, but on the other hand may facilitate infectivity,
as well as utilization of CXCR4, a homeostatic chemokine
receptor with a much wider in vivo distribution than CCR5
(20). Thus, our results corroborate the hypothesis that a low-
ered antibody-mediated selective pressure may be one of the
factors favoring the phenotypic switch from CCR5 to CXCR4
usage during the progression of HIV-1 disease.
The epitope recognized by MAb D19 is the first example, to
our knowledge, of a bona fide CD4-induced epitope mapping
to the V3 loop of HIV-1, although this definition applies se-
lectively to strains that depend on CCR5 for entry. In fact,
other known CD4i epitopes of gp120 map to the highly con-
served “bridging-sheet” surface and do not apparently differ-
entiate between CCR5-restricted and CXCR4-using strains
(56, 65, 67). Within the V3 loop, the D19 epitope appears to be
unique, as none of the V3-specific antibodies tested in our
study or reported previously (5, 9, 15, 17-19, 28, 34, 37, 39, 45,
47, 52, 58, 59) shows an identical reactivity pattern. Specifically,
none of the epitopes recognized by other MAbs displays the
same dichotomous behavior as MAb D19 in CCR5- versus
CXCR4-using HIV-1 isolates.
The structural basis of the cryptic nature of the D19 epitope
in R5 isolates remains unknown, although it may be related
either to an alternative conformation of the V3 region or to
steric occlusion by other gp120 structures. Our results with
monomeric gp120 imply that D19 epitope shielding is directly
related to the oligomeric structure of the HIV-1 Env. It is well
documented that several gp120 epitopes are markedly less
exposed on the Env oligomer than on the monomer (15, 37, 42,
53), fingering oligomerization as one of the most efficacious
strategies enacted by HIV-1 to protect critical neutralization
targets on the external Env surface. Indeed, the reactivity of
antibodies with monomeric gp120 is not predictive of their
capacity to bind the Env spikes or, therefore, of their neutral-
izing capability (15, 33, 37, 38, 42, 47, 53, 59). Oligomerization-
mediated epitope protection may be achieved, at least in part,
through the extensive glycosylation of the exposed surface of
gp120. Accessibility of the D19 epitope can be induced upon
binding of native Env to CD4, which causes dramatic confor-
mational changes in gp120, including displacement of the
prominent V1/V2-loop structure, as well as stabilization and/or
de novo formation of the “bridging sheet” that is the major
coreceptor-binding interface of gp120 (27, 44). Previous work
with V1/V2 loop-deleted mutants has documented the critical
role of this structure in concealing the coreceptor-binding re-
gion (3, 55, 65), which includes a portion of the V3 loop (34,
44, 57, 63, 64). Thus, we can speculate that in the Env oligo-
meric conformation the V3 loop in each protomer may be
partially shrouded by the V1/V2 loop from a neighboring pro-
tomer or, alternatively, that within each protomer the trimeric
structure forces the V1/V2 loop into a constrained position,
resulting in an intrinsically more protected conformation of the
entire coreceptor-binding region. The concept that the V3 loop
is more accessible in monomeric gp120 was indirectly con-
firmed by mouse immunization studies using oligomeric gp140,
which yielded markedly lower numbers of V3-directed MAbs
than using monomeric gp120 (7% versus 50%, respectively, of
the total) (14). Studies are under way to evaluate the impact of
V1/V2-loop truncation or of targeted deglycosylation of gp120
on the antibody accessibility of the D19 epitope.
Analysis of a large panel of primary HIV-1 isolates of dif-
ferent genetic subtypes showed that, despite its cryptic confor-
mation in the native R5 Env, the D19 epitope is relatively well
conserved, being present in more than half of the viral isolates
tested, as previously documented for other V3 epitopes (2, 5, 9,
18, 19, 39). Of note, primary HIV-1 isolates recognized by
MAb D19 were found within three different genetic subtypes
(A, B, and F). The conservation of selected V3 loop epitopes,
which is critical for the direct interaction of this domain with
the highly conserved coreceptor molecules, most likely results
from both secondary and tertiary structural elements. Evi-
dence suggesting a critical role of the tridimensional structure
in the antigenic makeup of the V3 loop was obtained in studies
with escape mutants (13, 35, 40), as well as with natively folded
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V3 chimeric proteins (24). By comparing the amino acid se-
quences of MAb D19-reactive and -nonreactive HIV-1 iso-
lates, we were unable to identify specific motifs, besides the
R3Q substitution at the tip of the loop, that were consistently
associated with reactivity or nonreactivity, reinforcing the con-
cept that the structural configuration of the loop, besides its
primary sequence, is critical for D19 epitope integrity. Unfor-
tunately, no high-resolution structural information of the V3
loop within the context of the native HIV-1 Env is currently
available, as gp120 crystals could only be obtained thus far
after truncation of this and other variable loops (27). However,
recent nuclear magnetic resonance and crystal structural data
on molecular complexes between V3-derived linear peptides
and a fragment of the broadly reactive human MAb 447-52D
have provided new insights into the structure of the V3 loop
(51, 54). According to these models, the distal portion of the
V3 loop adopts a -hairpin conformation, consisting of two
antiparallel -strands (residues K10-I14 and A19-T23) linked by
either an inverse -turn (51) or a type II -turn (54) and
corresponding to the highly conserved GPG motif at the tip of
the loop. In the crystal structure, the peptide N-terminal
-strand has extensive main-chain interactions with the anti-
body CDR3 H3 loop, resulting in the formation of a three-
stranded mixed -sheet (54). Interestingly, the 447-52D
epitope is partly conformation dependent, as shown by its
higher binding affinity for a folded V3 fusion protein than for
linear V3 peptides (19). Since our peptide mapping analysis
showed that the D19 epitope requires the presence of se-
quences on both sides of the GPG motif for its integrity, it is
plausible that MAb D19 recognizes the conserved -hairpin
structure of the V3 loop, but it is unable to bind to any purely
linear sequences. This hypothesis is corroborated by the ob-
served loss of MAb D19 reactivity with HIV-1 isolates display-
ing nonconservative substitutions in the C-terminal -strand of
the putative hairpin structure, which may result in the disrup-
tion of the strand conformation.
In conclusion, our data illustrate a novel mechanism of
epitope protection that is differentially implemented by the
two major biological variants of HIV-1. This novel paradigm
may provide a physiological key for interpreting the viral phe-
notypic switch that occurs in a proportion of patients during
the progression of the disease, as well as for elucidating the
relative role played by R5- versus CXCR4-using isolates in the
natural history of HIV-1 disease. Further studies will be im-
portant to verify this hypothesis in vivo, by correlating the
emergence of CXCR4-tropic viral strains with a lowered hu-
moral surveillance against this V3 loop epitope or other Env
epitopes that may differentially accessible in R5- versus
CXCR4-using HIV-1 strains. Regarding the efforts aimed at
developing a protective vaccine against HIV-1, our data pro-
vide further ground to the recent rehabilitation of the V3 loop
as a potential vaccine target, confirming the presence of
broadly conserved neutralization epitopes in this region. The
fact that the majority of subtype B isolates, but none of the
subtype C or E isolates, was recognized by MAb D19 suggests
that different serotypes may be defined based on epitopes
present in this region, all of which should be adequately rep-
resented to generate a broadly effective vaccine. However, the
cryptic nature of the D19 epitope in all R5 isolates, those
accounting for the vast majority of HIV-1 transmissions world-
wide, will reduce the potential value of at least this specific V3
epitope for the induction of protective neutralizing antibodies.
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